Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
EPS $-0.01 · Revenue $0.00
EPS $-0.01 · Revenue $0.00
EPS $-0.00 · Revenue $0.00
EPS $-0.01 · Revenue $0.00
EPS $-0.00 · Revenue $0.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-3.6M | +16.7% | -207.3% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-3.3M | +18.5% | — |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 11.2% | +973.7% | +182.8% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 7.39x | -82.4% | -80.8% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $5.8M | -31.8% | -47.6% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | — | — | — | — |
| Revenue Surprise | — | — | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| May 27, 2026 | LO WILLIAM WING YAN DR | director | Stock option (right to purchase) | D | 70,600 | $0.84 |
| May 27, 2026 | HUI EVANA YEE WAH | director | Stock option (right to purchase) | D | 19,000 | $0.25 |
| Mar 18, 2026 | LO WILLIAM WING YAN DR | director | Stock option (right to purchase) | — | 592,230 | $0.84 |
| Mar 18, 2026 | LO MARGARET HOOR HAN | director | Ordinary shares, par value $0.00001 | — | 0 | — |
| Mar 18, 2026 | LO MARGARET HOOR HAN | director | Stock option (right to purchase) | — | 592,230 | $17.40 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Wai Hong Chung | Chief Operating Officer, Chief Strategy Officer & Director | USD 245,642 | Male | 1978 | Active |
Yat-Gai Au | Founder, Chairman & Chief Executive Officer | — | Male | 1973 | Active |
Yat-Pui Au | Chief Business Officer | — | Male | 1975 | Active |
Antonia Assang | Senior Vice President of Project Management | — | Female | — | Active |
Michelle Chan | Financial Controller, Chief Financial Officer & Principal Financial Officer | — | Female | — | Active |
RGC Resources is a micro-cap natural gas utility with limited growth prospects and a small, stable service area. RGCO's earnings growth remains sluggish, with FY 2026 guidance implying just 1.2% year-over-year EPS growth and a PE of 15.7. The company offers a 4.04% forward dividend yield, supported by an 82-year dividend history and consistent annual payout increases.
RGC Resources NASDAQ: RGCO reported fiscal 2026 third-quarter net income of about $550,000, or $0.05 per diluted share, as higher margins supported results despite uneven weather patterns, increased operating expenses and the loss of a large industrial customer.
ROANOKE, Va., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated earnings of $559,000, or $0.05 per diluted share, for the third quarter ended June 30, 2026, compared to $538,000, or $0.05 per diluted share, for the third quarter ended June 30, 2025. Operating margin for the third quarter was $757,000 higher than the equivalent period a year earlier aided by higher non-gas base rates that became effective January 1, 2026. Operating expenses were higher by a similar amount resulting in a nominal decline in operating earnings.
Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant treatment gaps. I reiterate a Strong Sell on RGC, citing reliance on cost-cutting, high dilution risk, and a DOJ trading investigation overhang. RGC's valuation is unsustainable without externally validated clinical and commercial progress; shares have collapsed ~73% after a prior speculative surge.
ROANOKE, Va., June 29, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of RGC Resources, Inc. (Nasdaq: RGCO) declared a quarterly dividend of $0.2175 per share on the Company's common stock. The dividend will be paid on August 3, 2026 to shareholders of record on July 17, 2026. This is the Company's 329th consecutive quarterly cash dividend.
